Hemant Surgical Industries Limited has disclosed a press release pursuant to Regulation 30 of SEBI LODR Regulations regarding a strategic acquisition.
The company has completed the acquisition of a majority 66.66% stake in Lifesenz Cancer Research Labs Private Limited ("Lifesenz") for an amount of ₹19.98 Crores. This transaction makes Lifesenz a subsidiary of Hemant Surgical with effect from June 01, 2026.
Lifesenz operates in the field of precision oncology, specializing in advanced ex-vivo chemo-sensitivity analysis using patient-derived 3D cancer cell models. This technology assists clinicians in evaluating the effectiveness of different treatment options before therapy administration.
The acquisition represents a strategic move to expand beyond traditional healthcare distribution into emerging areas of advanced diagnostics and precision medicine. The company expects this integration to create opportunities for expanding participation in specialized healthcare and oncology markets, strengthening relationships with hospitals and healthcare institutions, and enhancing the portfolio with differentiated healthcare solutions.
Management acknowledges that Lifesenz is currently in a growth and development phase and will take some time to break even and eventually add financial synergies to the company. The acquisition was evaluated through a long-term strategic lens rather than near-term profitability metrics, and was completed on an arm's length basis.
The company intends to support Lifesenz through scaling operational capabilities, strengthening clinical and institutional collaborations, expanding patient adoption, increasing commercialization opportunities, and supporting innovation in precision oncology.
Mr. Hanskumar Shamji Shah, Managing Director, commented: "Precision oncology is an area of significant clinical importance and growing global relevance. The acquisition of Lifesenz reflects our commitment to participate in the future of healthcare. By combining Lifesenz's scientific expertise with Hemant Surgical's established healthcare platform, we are creating a foundation for long-term growth while contributing to improved patient care outcomes."
The press release contains forward-looking statements regarding future business prospects, expected synergies, growth opportunities, and market developments, with the disclaimer that actual results may differ materially due to market conditions, regulatory developments, execution risks, and other factors beyond the company's control.